You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

Prednisolone sodium phosphate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for prednisolone sodium phosphate and what is the scope of freedom to operate?

Prednisolone sodium phosphate is the generic ingredient in thirteen branded drugs marketed by Merck, Watson Labs, Novartis, Schering, Pharmafair, Alcon Pharms Ltd, Bausch And Lomb, Epic Pharma Llc, Sola Barnes Hind, Concordia Pharms Inc, Seton Pharm, Amneal, Amneal Pharms, Bausch, Chartwell Rx, Edenbridge Pharms, Hikma, Mission Pharma, Nesher Pharms, Ph Health, Pharm Assoc, Pharmobedient, Pharmobedient Cnsltg, Vintage Pharms, We Pharms, Advanz Pharma, Rising, and Genus, and is included in forty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for prednisolone sodium phosphate. Eighteen suppliers are listed for this compound.

Recent Clinical Trials for prednisolone sodium phosphate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Huro Biotech Joint Stock CompanyN/A
Vietstar Biomedical ResearchN/A
University of OuluPhase 4

See all prednisolone sodium phosphate clinical trials

Pharmacology for prednisolone sodium phosphate
Anatomical Therapeutic Chemical (ATC) Classes for prednisolone sodium phosphate
A01AC Corticosteroids for local oral treatment
A01A STOMATOLOGICAL PREPARATIONS
A01 STOMATOLOGICAL PREPARATIONS
A Alimentary tract and metabolism
A06AD Osmotically acting laxatives
A06A DRUGS FOR CONSTIPATION
A06 DRUGS FOR CONSTIPATION
A Alimentary tract and metabolism
A06AG Enemas
A06A DRUGS FOR CONSTIPATION
A06 DRUGS FOR CONSTIPATION
A Alimentary tract and metabolism
A07EA Corticosteroids acting locally
A07E INTESTINAL ANTIINFLAMMATORY AGENTS
A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A Alimentary tract and metabolism
B05XA Electrolyte solutions
B05X I.V. SOLUTION ADDITIVES
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B Blood and blood forming organs
C05AA Corticosteroids
C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05 VASOPROTECTIVES
C Cardiovascular system
D07AA Corticosteroids, weak (group I)
D07A CORTICOSTEROIDS, PLAIN
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D Dermatologicals
D07XA Corticosteroids, weak, other combinations
D07X CORTICOSTEROIDS, OTHER COMBINATIONS
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D Dermatologicals
H02AB Glucocorticoids
H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02 CORTICOSTEROIDS FOR SYSTEMIC USE
H Systemic hormonal preparations, excluding sex hormones and insulins
R01AD Corticosteroids
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
S01BA Corticosteroids, plain
S01B ANTIINFLAMMATORY AGENTS
S01 OPHTHALMOLOGICALS
S Sensory organs
S01CB Corticosteroids/antiinfectives/mydriatics in combination
S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
S01 OPHTHALMOLOGICALS
S Sensory organs
S02BA Corticosteroids
S02B CORTICOSTEROIDS
S02 OTOLOGICALS
S Sensory organs
S03BA Corticosteroids
S03B CORTICOSTEROIDS
S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S Sensory organs
V03AG Drugs for treatment of hypercalcemia
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V Various
Paragraph IV (Patent) Challenges for PREDNISOLONE SODIUM PHOSPHATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ORAPRED ODT Orally Disintegrating Tablets prednisolone sodium phosphate 10 mg, 15 mg and 30 mg 021959 1 2010-07-22

US Patents and Regulatory Information for prednisolone sodium phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Seton Pharm PEDIAPRED prednisolone sodium phosphate SOLUTION;ORAL 019157-001 May 28, 1986 AA RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Pharm Assoc PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate SOLUTION;ORAL 078465-001 Mar 7, 2008 AA RX No Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Mission Pharma PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate SOLUTION;ORAL 091396-001 Sep 13, 2010 AA RX No Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Bausch And Lomb SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate; sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 074449-001 Dec 29, 1995 RX No Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Sola Barnes Hind PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate SOLUTION/DROPS;OPHTHALMIC 084169-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Edenbridge Pharms PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate SOLUTION;ORAL 203559-003 Feb 6, 2023 AA RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for prednisolone sodium phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Advanz Pharma ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ⤷  Get Started Free ⤷  Get Started Free
Advanz Pharma ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ⤷  Get Started Free ⤷  Get Started Free
Seton Pharm PEDIAPRED prednisolone sodium phosphate SOLUTION;ORAL 019157-001 May 28, 1986 ⤷  Get Started Free ⤷  Get Started Free
Advanz Pharma ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ⤷  Get Started Free ⤷  Get Started Free
Advanz Pharma ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ⤷  Get Started Free ⤷  Get Started Free
Advanz Pharma ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Market Dynamics and Financial Trajectory for Prednisolone Sodium Phosphate

Last updated: November 19, 2025

Introduction

Prednisolone sodium phosphate, a soluble corticosteroid, is widely used in clinical settings to manage various inflammatory and autoimmune conditions, including allergic reactions, adrenal insufficiency, and certain neoplasms. As an injectable corticosteroid, its rapid onset and potent anti-inflammatory effects have cemented its position within specialty therapeutic areas. This article examines the evolving market landscape and financial prospects of prednisolone sodium phosphate, driven by clinical needs, regulatory developments, and competitive dynamics.

Market Overview and Key Drivers

Clinical Demand and Therapeutic Applications

Prednisolone sodium phosphate remains vital in acute care and emergency settings due to its rapid systemic absorption when administered intravenously. Its efficacy in managing severe allergic reactions, acute asthma exacerbations, and cerebral edema sustains consistent demand. The expanding prevalence of autoimmune diseases, allergies, and respiratory conditions globally fuels a baseline market need.

The increasing adoption of corticosteroids in oncology-related supportive care further amplifies its utilization. Additionally, the rising incidence of autoimmune disorders, such as rheumatoid arthritis and lupus, correlates with steady growth in corticosteroid prescriptions, including formulations like prednisolone sodium phosphate.

Regulatory Environment

Regulatory agencies worldwide have maintained stringent standards for corticosteroid formulations, emphasizing safety and efficacy. Recent approvals of generic versions and biosimilars in emerging markets have heightened competition, leading to price reductions and expanded access. Conversely, regulatory focus on minimizing adverse effects, particularly in long-term use, influences prescribing trends and product development.

Competitive Landscape

The corticosteroid market is highly fragmented, featuring numerous branded and generic products. Prednisolone sodium phosphate competes primarily on rapid onset and bioavailability. Major pharmaceutical companies and local manufacturers dominate the space, with key differentiators including formulation stability, manufacturing quality, and cost.

The advent of targeted drug delivery systems and novel corticosteroid derivatives may reshape competitive dynamics, although prednisolone sodium phosphate continues to hold relevance owing to its well-established profile and manufacturing infrastructure.

Market Challenges

  • Safety Concerns: Corticosteroid-related adverse events, such as immunosuppression, osteoporosis, and hyperglycemia, influence prescribing habits and patient management strategies. The potential for long-term adverse effects limits excessive use and prompts interest in alternative therapies.

  • Pricing Pressures: Increased generic competition has driven down prices, impacting profit margins for manufacturers. Governments and healthcare providers' emphasis on cost containment further constrains pricing.

  • Supply Chain Stability: Manufacturing complexities related to sterile injectable products pose risks. Disruptions in raw materials or manufacturing capacities can impact availability, particularly in emerging markets.

Market Opportunities

  • Emerging Markets: Growing healthcare infrastructure and increasing healthcare expenditure in Asia-Pacific, Latin America, and Africa open avenues for expanding access and sales.

  • Inhalation and Topical Formulations: Innovations in alternative delivery routes may broaden the therapeutic applications and market footprint.

  • Post-Marketing Surveillance and Safety Profiles: Enhanced safety data can bolster confidence among clinicians, leading to sustained or increased utilization.

  • Partnerships and Licensing: Strategic alliances for manufacturing, distribution, and R&D can facilitate market penetration and product innovation.

Financial Trajectory and Market Forecast

Revenue Projections

The corticosteroid injectable segment, including prednisolone sodium phosphate, is projected to witness a compound annual growth rate (CAGR) of approximately 3–5% over the next five years. Market value, estimated at USD 200-300 million in 2022, is expected to surpass USD 350 million by 2027, driven by increasing demand in acute care settings.

Regional Outlook

  • North America: The mature market benefits from high healthcare expenditure and established regulatory pathways. Growth stems from expanding indications and aging populations.

  • Europe: Similar to North America, with additional influence from stringent regulatory standards and biosimilar competition.

  • Asia-Pacific: Rapidly growing markets present significant upside, driven by increases in healthcare access and emerging clinical practices.

  • Latin America and Africa: Market expansion opportunities are tempered by infrastructural challenges but are increasingly attractive owing to rising disease prevalence and drug affordability initiatives.

Profit Margins and Cost Dynamics

Manufacturing costs are influenced by the complexities of sterile injectable production, raw material sourcing, and quality assurance. Generic manufacturers offer competitive prices, pressuring profit margins for innovator companies. Nonetheless, strong demand in acute and emergency care sustains overall revenue streams.

Strategic Considerations

To capitalize on market opportunities, pharmaceutical entities should prioritize:

  • Streamlining Supply Chains: Ensuring manufacturing resilience and raw material sourcing stability.

  • Investing in Safety and Efficacy Data: Supporting clinical evidence can bolster market share amid safety concerns.

  • Expanding Market Access: Tailoring strategies for emerging markets through partnerships and local manufacturing.

  • Innovating Delivery Methods: Developing alternative formulations to expand therapeutic use cases.

Key Market Trends

  • Growth in corticosteroid prescribing driven by rising autoimmune and allergic diseases.
  • Increasing reliance on biosimilars and generics to reduce costs.
  • Emphasis on pharmacovigilance to mitigate safety concerns.
  • Technological advancements in production enhancing quality and scalability.
  • Regulatory harmonization facilitating international market entry.

Key Takeaways

  • Stable Demand: Prednisolone sodium phosphate remains essential in acute medical care, ensuring consistent demand.

  • Price Sensitivity: Generic competition and cost containment practices impose pressure on pricing and margins.

  • Emerging Market Expansion: Asia-Pacific and Latin America offer high growth potential due to increasing healthcare infrastructure.

  • Innovation Focus: Developing delivery systems and safety profiles can sustain and enhance market position.

  • Regulatory Dynamics: Ongoing regulatory oversight influences market access and product differentiation strategies.

Conclusion

The market trajectory for prednisolone sodium phosphate is characterized by steady growth, primarily driven by clinical utility, regulatory evolution, and regional expansion. While challenges persist—particularly concerning safety concerns and pricing pressures—strategic innovations and targeted market access initiatives position the pharmaceutical industry well to capitalize on emerging opportunities. The ongoing demand in acute and autoimmune care, combined with advances in manufacturing and formulations, forecast a resilient financial outlook for this critical corticosteroid formulation.


FAQs

1. What factors are influencing the demand for prednisolone sodium phosphate?
The increasing prevalence of autoimmune, allergic, and inflammatory conditions, alongside its essential role in emergency and acute care, sustains demand. Additionally, expanding healthcare access in emerging markets further amplifies usage.

2. How does generic competition impact the market for prednisolone sodium phosphate?
Generic manufacturers exert downward pressure on prices, reducing profit margins but expanding accessibility. Competition also accelerates innovation in formulations and delivery methods to differentiate products.

3. What are the primary challenges facing the prednisolone sodium phosphate market?
Key challenges include safety concerns related to corticosteroid adverse effects, pricing pressures from generics, manufacturing complexities, and supply chain stability issues.

4. Which regions offer the greatest growth opportunities for prednisolone sodium phosphate?
Emerging markets in Asia-Pacific, Latin America, and Africa present significant growth potential due to increasing healthcare infrastructure and rising disease burdens.

5. How might future innovations influence the market?
Development of alternative delivery systems, improved safety profiles, and biosimilar competition will shape the competitive landscape, potentially unlocking new therapeutic applications and market segments.


References

[1] Market research reports on corticosteroid injectables.
[2] Regulatory agency publications and updates.
[3] Industry analyst insights and market trend analyses.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.